The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
News|Articles|February 2, 2026
FDA updates in urology: January 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from January 2026.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! The year began with a couple of notable regulatory updates, including fast track designation for a novel platform that can deliver enzalutamide (Xtandi) directly into prostate tissue as well as FDA clearance for a new kidney stone device.
Related to this article
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
This FAQ outlines key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.
Advertisement
Advertisement